| Considerations for the use of phage therapy in clinical practice GA Suh, TP Lodise, PD Tamma, JM Knisely, J Alexander, S Aslam, ... Antimicrobial agents and chemotherapy 66 (3), e02071-21, 2022 | 189 | 2022 |
| Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections NC Warner, LA Bartelt, AM Lachiewicz, KM Tompkins, MB Miller, K Alby, ... Clinical Infectious Diseases 73 (7), e1754-e1757, 2021 | 36 | 2021 |
| Overcoming Stenotrophomonas maltophilia Resistance for a More Rational Therapeutic Approach R Kullar, E Wenzler, J Alexander, EJC Goldstein Open Forum Infectious Diseases 9 (5), ofac095, 2022 | 24 | 2022 |
| Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections D Holger, R Kebriaei, T Morrisette, K Lev, J Alexander, M Rybak Antibiotics 10 (5), 556, 2021 | 20 | 2021 |
| Bacteriophage‐antibiotic combination therapy for multidrug‐resistant Pseudomonas aeruginosa: In vitro synergy testing DJ Holger, KL Lev, R Kebriaei, T Morrisette, R Shah, J Alexander, ... Journal of Applied Microbiology 133 (3), 1636-1649, 2022 | 15 | 2022 |
| 1607. Dual therapy with aztreonam & ceftazidime/avibactam against multi-drug resistant Stenotrophomonas maltophilia on tricuspid valve endocarditis J Alexander, A Carr, SB Minor, D Navas Open Forum Infectious Diseases 7 (Suppl 1), S798, 2020 | 4 | 2020 |
| Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models DJ Holger, A El Ghali, N Bhutani, KL Lev, K Stamper, R Kebriaei, ... Antimicrobial Agents and Chemotherapy 67 (11), e00578-23, 2023 | 2 | 2023 |
| 1026. Following the hoof prints: detecting Coxiella and Brucella infections with a plasma-based microbial cell-free DNA next-generation sequencing test NR Degner, R Castillo-Galvan, J Alexander, A Arun, CR de Vries, ... Open Forum Infectious Diseases 8 (Suppl 1), S604, 2021 | 2 | 2021 |
| 1615. Isolation of Lytic Bacteriophages with Broad Host Range Activity Against Pseudomonas aeruginosa Strains Isolated from Respiratory Samples from Cystic Fibrosis Patients … J Alexander, D Navas, M Flowers, A Charles, A Carr Open Forum Infectious Diseases 7 (Suppl 1), S801, 2020 | 2 | 2020 |
| Antibacterial Resistance Leadership G. 2022 GA Suh, TP Lodise, PD Tamma, JM Knisely, J Alexander, S Aslam, ... Considerations for the use of phage therapy in clinical practice. Antimicrob …, 0 | 2 | |
| Ciprofloxacin in combination with bacteriophage cocktails against multi-drug resistant Pseudomonas aeruginosa in ex vivo simulated endocardial vegetation models A El Ghali, K Stamper, AJ Kunz Coyne, D Holger, R Kebriaei, J Alexander, ... Antimicrobial Agents and Chemotherapy 67 (11), e00728-23, 2023 | 1 | 2023 |
| 663. Two (Plus) Birds, One Stone: The Rapid, Comprehensive, Non-invasive Detection of Co-Pathogens of Critical Importance Using A Plasma-based Microbial Cell-free DNA Next … M Smollin, MS Lindner, NR Degner, R Castillo-Galvan, J Alexander, ... Open Forum Infectious Diseases 8 (Supplement_1), S433-S434, 2021 | 1 | 2021 |
| 1030. Chasing the Long Tail of Infectious Diseases: Detecting Capnocytophaga canimorsus and Pasteurella multocida Infections with A Plasma-based Microbial … NR Degner, R Galvan-Castillo, J Alexander, A Arun, CR de Vries, ... Open Forum Infectious Diseases 8 (Supplement_1), S605-S606, 2021 | 1 | 2021 |
| 2745. In-Vitro Activity of Cefiderocol Against Multidrug Resistant Strains of P. aeruginosa DTR, A. baumannii complex DTR, A. xylosoxidans MDR, S. maltophilia MDR & B. cepacia … J Alexander, D Navas, A Charles Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2356, 2023 | | 2023 |
| 1691. Bacteriophage and Protein Synthesis Pathway Inhibitor Combinations: Antibiotic mechanism of action drives antagonistic interactions AJ Kunz Coyne, N Bhutani, D Holger, R Kebriaei, K Stamper, AE Ghali, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 1321, 2022 | | 2022 |
| 132. Evaluation Phage Cocktails in Combination with Ciprofloxacin Against Multidrug-Resistant Pseudomonas aeruginosa Overexpressing MexAB-OprM Efflux Systems D Holger, K Lev, N Bhutani, R Kebriaei, T Morrisette, S Lehman, ... Open Forum Infectious Diseases 8 (Suppl 1), S81, 2021 | | 2021 |
| 673. Unbiased Microbial Cell-free DNA Next-Generation Sequencing Resolves HHV6 Variant Specificity and Demonstrates a Predominance of HHV6B over HHV6A in Real-World Clinical … J Alexander, S Bercovici, NR Degner, R Castillo-Galvan, A Arun, ... Open Forum Infectious Diseases 8 (Supplement_1), S438-S439, 2021 | | 2021 |
| 1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa D Navas, A Charles, A Carr, J Alexander Open Forum Infectious Diseases 7 (Suppl 1), S655, 2020 | | 2020 |
| 649. Clinical Implementation of a Rapid Susceptibility Testing Procedure, Directly From a Positive Blood Culture Using the Vitek® 2 System on Gram Negative Rods C Henry, D Evans, D Navas, A Barker, C Somyos, M Rodriguez, ... Open Forum Infectious Diseases 7 (Supplement_1), S383-S383, 2020 | | 2020 |
| 1601. Combination Therapy versus Monotherapy for Carbapenem-resistant Organisms: Is More Really Better? L Najia, A Carr, J Alexander, SB Minor Open Forum Infectious Diseases 7 (Suppl 1), S796, 2020 | | 2020 |
